Millennium Laboratories Awarded Testing Agreement with Progressive Medical
Progressive Medical to use Millennium UDT to help address increase in prescription opioid use among workers´ compensation populations.
San Diego and Westerville, Ohio (PRWEB) April 15, 2013
Millennium Laboratories, the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain and/or addiction, and Progressive Medical, Inc., a leading workers´ compensation pharmacy benefit manager, today announced a collaboration for servicing workers´ compensation claimants. Millennium Laboratories is now a preferred provider in Progressive Medical´s network that will provide its clients with medication monitoring and drug detection testing services.
“We are pleased to have Millennium Laboratories become part of our comprehensive urine drug monitoring network,” said Progressive Medical´s Chief Clinical Officer Tron Emptage. “This relationship with Millennium helps us fulfill our mission to reduce costs and ensure appropriate treatment by providing tools for clients and physicians to improve care and monitor adherence to medication therapy.”
With the use of opioid analgesics on the rise among the workers´ compensation population, payers in this market face unique challenges. The agreement means that Millennium´s industry leading services can be used by prescribers treating injured workers for chronic pain and/or addiction to determine and document their use of prescribed medications and substances. Armed with this data, physicians may more safely and effectively improve outcomes for these individuals, helping them get back to work and resume productive, quality lives.
Prescription drug abuse results in one death every 19 minutes in the U.S.1 Workers´ compensation claimants using opioids chronically have healthcare costs that are more than four times those of claimants not using opioids.2. For 90 days or longer, odds of chronic work loss are 11—14 times more likely for claimants with opioid prescriptions compared to those without opioids.3.
“Millennium´s medication monitoring and drug detection testing services will enable Progressive Medical clients to have a better understanding of the medications and drugs an injured worker may or may not be taking, help identify possible drug-drug interactions and often can help initiate a broader conversation about the individual´s physical and mental health,” said Millennium Laboratories´ Vice President, Managed Markets and Workers´ Comp, Brent Gibbs. “We are thrilled to have our product and service offerings become part of Progressive Medical´s promise to lower costs and improve care.”
About Progressive Medical, Inc.
Progressive Medical promises the lowest total program cost through more control and better outcomes. As a leader in the workers´ compensation PBM industry, we believe it´s our responsibility to make a difference; to look at every aspect of the business with fresh eyes. This means looking for ways to reduce total PBM cost, reinvent relationships, combine analytics with clinical innovation and advocate industry-supporting public policy. Doing what´s best for both clients and injured workers alike. Visit http://www.progressive-medical.com to learn more.
About Millennium Laboratories
Millennium Laboratories is the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain and/or addiction. The company provides healthcare professionals with medication monitoring, drug detection and pharmacogenetic testing services to personalize treatment plans to improve clinical outcomes and patient safety. More information can be found at http://www.millenniumlabs.com.
(2) Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care. 2011;17(1):32-40.
(3) Volinn E, Fargo JD, Fine PG. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. Pain. 2009;142(3):194-201.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10631142.htm